Bausch Health Shares Jump 21% After Third-Quarter Profit Beat and Higher Guidance

what happened

Bausch Health shares climbed 21% in Toronto, to 11.72 Canadian dollars ($8.37), after the drugmaker posted third-quarter profit above expectations and lifted its guidance, Dow Jones Newswires reported.

Revenue rose 10% to $2.94 billion, versus analyst forecasts of $2.75 billion. Net income was $436 million, up from $179 million a year earlier, and adjusted earnings reached $1.77 a share against $1.27 expected. Strong demand for Xifaxan, the main growth driver in the Salix segment, lifted that unit's revenue 16% to $831 million. Solta revenue grew 18% to $165 million, and international sales rose 5% to $299 million.

For the full year the company now expects revenue of $10.98 billion to $11.18 billion, compared with the earlier $10.79 billion to $11.04 billion. Adjusted EBITDA is now projected at $4.32 billion to $4.42 billion, up from $4.05 billion to $4.18 billion.

why it matters

The report signals resilience in the core gastroenterology business, where Xifaxan is driving growth. Raised guidance typically resets analyst expectations for the stock, and the clear beat on revenue and profit points to strong demand across Salix and international markets.

market impact

Bausch Health shares: strong results and raised guidance support the stock

• ▲Bausch Health shares pressure up — profit and revenue beat forecasts and the company raised its full-year outlook

tags

instruments